// App-Quantinova.ai

CT151 : Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Researchers

Presenter

  • Apostolia M. Tsimberidou

Principal Investigators

  • Philip Beer

  • Jennifer Bendall

  • James Dow

  • Justine King

  • Hilary McElwaine-Johnn

  • Ignacio I. Wistuba

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • PsiOxus Therapeutics Ltd., Abingdon, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03008018

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved